Newsmeme!
Discover News you didn't know existed
Biogen Idec announced the US Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS). Biogen Idec is currently enrolling patients in a global phase-III study evaluating the efficacy and safety of either bi-weekly or once-monthly injections of PEGylated interferon beta-1a in this patient population.
Findings of a Danish study suggest the use of proton pump inhibitors can produce acid-related symptoms in healthy adults. Proton pump inhibitors are a group of drugs used to cause a pronounced and long-lasting reduction of gastric acid production and are among the most widely selling drugs in the world, Wikipedia said. But results of an eight-week, randomized, double-blind placebo-controlled ...
SEATTLE, July 9 /PRNewswire/ -- Dharma Therapeutics, Inc., ("Dharma") Seattle, WA (a subsidiary of the Transcu Group Limited, a company listed on the Singapore Exchange Limited) announced that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, has demonstrated safety and efficacy in a Phase 2 clinical ...
Severe acute malnutrition affects 13 million children worldwide and causes 1—2 million deaths every year. Our aim was to assess the clinical and nutritional efficacy of a probiotic and prebiotic functional food for the treatment of severe acute malnutrition in a HIV-prevalent setting.
NASA: Spirit still stuck in Martian sand ... Antacid drugs may lead to dependency … Frozen carbon a climate change threat … Cancer, non-cancer cells have similarities ... Health/Science news from UPI.
VANCOUVER, BRITISH COLUMBIA--(Marketwire - July 9, 2009) - Allon Therapeutics Inc. (TSX:NPC) today released top-line results from a Phase IIa clinical trial showing that the Company's lead neuroprotective drug candidate, davunetide intranasal (AL-108), has a positive impact on the ability of schizophrenia patients to carry out important activities in their daily lives. Allon said statistically ...
VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. today released top-line results from a Phase IIa clinical trial showing that the Company's lead neuroprotective drug candidate, davunetide intranasal , has a positive impact on the ability of schizophrenia patients to carry out important activities in their daily lives.
Dharma Therapeutics, Inc., Seattle, WA announced that its improved active transdermal delivery technology, which administers lidocaine and epinephrine through the skin via a mild electric current, has demonstrated safety and efficacy in a Phase 2 clinical trial.
COPENHAGEN, Denmark, July 9 (UPI) -- Findings of a Danish study suggest the use of proton pump inhibitors can produce acid-related symptoms in healthy adults.
Biogen Idec (NASDAQ: BIIB) announced the U.S. Food and Drug Administration (FDA) has granted PEGylated interferon beta-1a (BIIB017) Fast Track designation for relapsing multiple sclerosis (RMS).
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |